MesoblastMESO
About: Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
Employees: 73
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
430% more call options, than puts
Call options by funds: $6.75M | Put options by funds: $1.27M
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
18% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 11
16% more capital invested
Capital invested by funds: $10.7M [Q2] → $12.4M (+$1.75M) [Q3]
10% more funds holding
Funds holding: 39 [Q2] → 43 (+4) [Q3]
0% less ownership
Funds ownership: 0.14% [Q2] → 0.14% (-0%) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Piper Sandler Edward Tenthoff 23% 1-year accuracy 10 / 43 met price target | 3%upside $15 | Overweight Maintained | 19 Dec 2024 |
Maxim Group Jason McCarthy 26% 1-year accuracy 7 / 27 met price target | 18%downside $12 | Buy Upgraded | 24 Sept 2024 |
Financial journalist opinion
Based on 9 articles about MESO published over the past 30 days
